Treatment of
infections by the use of
antimicrobial agents should be made essentially in a dose close to the minimally required dose. Acute uncomplicated
cystitis in female fits as the subject for a single-dose
therapy since it is an
infection reactive relatively easily to
antimicrobial agents. Accordingly, an assessment has been made regarding the therapeutic results of the single-dose
therapy in 76 female cases of acute uncomplicated
cystitis by the use of LVFX 200 mg which is a new
quinolone. The urinary concentration more than MIC90 to Escherichia coli is sustained for about 3 days by this single-dose
therapy. As a result of judging the therapeutic results from the reactions of the three clinical findings of
pain on micturition,
pyuria and
bacteriuria, excellent therapeutic results were obtained with effective rates being 100% (76/76) on the day 3, 93.9% (46/49) on the day 7 and 94.4% (34/36) on the day 14. The rate of cystitic symptoms which recurred posed no problem, being 12.5% (5/40) up to three months, as investigated by a questionnaire. As a result of performing close urological examinations such as cystoscopy on six cases with insufficient results or recurrence, we could detect mild underlying conditions which are considered to be intractable factors in the bladder in three cases. From the above results, the single-dose
therapy of acute uncomplicated
cystitis in the female by LVFX which is a new
quinolone was considered to be an excellent therapeutic
drug from its characteristics such as its therapeutic results being the same as the conventional
therapy by daily administration, excellent drug compliance, low cost, hard selectiveness of resistant strains, less side effects and furthermore it gives the opportunity of detecting a latent and mild underlying condition.